NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The global atopic dermatitis drugs market size is estimated to grow by USD 6.2 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 10.87% during the forecast period. High prevalence of atopic dermatitis is driving market growth, with a trend towards strategic partnerships and acquisitions.
However, side effects associated with corticosteroids poses a challenge.Key market players include AbbVie Inc., Arcutis Biotherapeutics Inc.
, Asana BioSciences LLC, Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, BiomX Inc.
, Bristol Myers Squibb Co., Dermavant Sciences Inc., Eli Lilly and Co.
, Evelo Biosciences Inc., Galderma SA, Incyte Corp., LEO Pharma AS, Maruho Co.
Ltd., Novartis AG, Otsuka Holdings Co. Ltd.
, Pfizer Inc., Sanofi SA, and Viatris Inc..
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Market Driver Vendors in the global atopic dermatitis drugs market have expanded their product offerings through strategic initiatives such as mergers and acquisitions and technology collaborations since 2019. For instance, Pfizer and Glenmark's introduction of Abrocitinib, an approved treatment for moderate-to-severe atopic dermatitis, in India and other regions, is a notable example.
Such partnerships and approvals contribute to market growth and potential profit .
